RT Journal Article
T1 IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
A1 Sancho, Juan-Manuel
A1 Marin-Niebla, Ana
A1 Fernandez, Silvia
A1 Capote, Francisco-Javier
A1 Cañigral, Carolina
A1 Grande, Carlos
A1 Donato, Eva
A1 Zeberio, Izaskun
A1 Puerta, Jose-Manuel
A1 Rivas, Alfredo
A1 Perez-Ceballos, Elena
A1 Vale, Ana
A1 Martin Garcia-Sancho, Alejandro
A1 Salar, Antonio
A1 Gonzalez-Barca, Eva
A1 Teruel, Anabel
A1 Pastoriza, Carmen
A1 Conde-Royo, Diego
A1 Sanchez-Garcia, Joaquin
A1 Barrenetxea, Cristina
A1 Arranz, Reyes
A1 Hernandez-Rivas, Jose-Angel
A1 Ramirez, Maria-Jose
A1 Jimenez, Aroa
A1 Rubio-Azpeitia, Eva
K1 Clinical practice
K1 Ibrutinib
K1 Mantle-cell lymphoma
K1 Real-world evidence
K1 Relapsed/refractory
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
AB This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1-2; min-max 1-7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7 months (range 5.2-19.6; min-max 0.3-36), the median progression-free survival (PFS) and overall survival (OS) were 20 months [95% confidence interval (CI) 8.8-31.1] and 32 months (95% CI 22.6-41.3), respectively, and were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL.
PB Springer
YR 2022
FD 2022-04-19
LK http://hdl.handle.net/10668/21263
UL http://hdl.handle.net/10668/21263
LA en
NO Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C, et al. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. Int J Hematol. 2022 Sep;116(3):381-392
DS RISalud
RD Apr 12, 2025